New cat vaccine eliminates allergic reactions in humans

Many cat lovers struggle with cat allergies, which cause various symptoms - from sniffing and runny nose to more severe reactions that can even send them to the emergency room. For some people, antiallergic drugs are enough, although they are not without side effects. Others simply suffer from the symptoms (and put up with it) in exchange for the privilege of having a cat in their home. We sincerely believe that cats are grateful for this. Others, however, prefer to stay away from cats to save themselves trouble.

Cat allergies - what are the symptoms

Allergies to cats are one of the most common allergies among humans. Allergic symptoms associated with this type of reaction to cats include coughing, wheezing, chest tightness, itching, stuffy nose, rash, eye tearing, sneezing and more. In the worst-case scenario, allergies to cats can develop into more life-threatening conditions such as rhinitis and mild to severe forms of asthma.

Practice has so far shown that allergies to cats can be controlled with the help of medications, immunotherapy injections and vaccines, such as that developed by the team of the Swiss company "HypoPet AG" (now "Saiba Animal Health"). In 2020, HypoCat's development and commercialization rights were transferred from Benchmark Holdings PLC to a leading global animal health company.  [ref. 1] 

Neutralisation of FEL D 1 is the core of the vaccine

According to the publication in the medical journal, cats live in about 25% of households in Western countries, and allergies to them affect about 10% of people nearby. The most common cat allergen is called 'Fel d 1', produced largely by the cat's sebaceous glands and is found in cat saliva, glands, sebaceous glands, skin and fur.

Fel-CuMVTT, which will be marketed as a HypoCat vaccine™ by the Swiss company HypoPet, was developed through a collaboration between researchers from the Latvian Center for Biomedical Research and Sciences in Riga and the Veterinary School at the University of Zurich – together with scientists from the Functional Center for Genomics - Zurich.   [Ref. 2] 

Image source: The Journal of Allergy and Clinical Immunology

Technology and benefits of the vaccine

The vaccine combines the recombinant Fel d 1 with a virus-like particle (or "VLP") derived from the virus of a cucumber mosaic virus.

"We are very pleased to publish data that shows that our HypoCat vaccine™ is able to produce high levels of antibodies in cats and that these antibodies can bind and neutralize the allergen Fel d 1 produced by animals," says Dr. Gary Jennings, CEO of HypoPet.

Cats treated with the vaccine were found to be less likely to cause allergic reactions in people exposed to them. It was also reported that the vaccine was "well tolerated without any apparent toxicity" to feline test subjects. The published data were derived from four separate studies involving 54 cats.

The benefits of effective treatment of cat allergy are not only for adults. First, these allergies are not only unpleasant - and sometimes very excruciating - but allergy to cats in children living with cats is considered a strong factor in the development of childhood asthma. A course that includes three doses of vaccine - as applied in testing - can alleviate the suffering of fluffy friends' owners and the risk to the youngest family members.  [ref. 3] 

Suggested